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(ages 1-5 years: adjusted hazard ratio [AHR] for each ad-
ditional week of gestation, 0.86 [95% CI, 0.80-0.94], P.001,
based on 120 deaths), which weakened and was nonsignifi-
cant in later childhood (ages 6-12 years: AHR, 0.90 [95%
CI, 0.73-1.10], P=.31, based on 21 deaths), adolescence (ages
13-17 years: AHR, 0.92 [95% CI, 0.75-1.11], P=.38, based
on 25 deaths), and young adulthood (ages 18-36 years: AHR,
0.90 [95% CI, 0.81-1.01], P=.07, based on 77 deaths). When
the latter 3 age ranges were combined to improve statisti-
cal power, there was a significant inverse association be-
tween gestational age at birth and infection-related mortal-
ity in this broader age range (ages 6-36 years: AHR, 0.91
[95% CI, 0.83-0.99], P=.02).
We also reexamined the association between gesta-
tional age at birth and respiratory mortality after exclud-
ing infection-related deaths (ie, censoring these individu-
als at the time of death). In early childhood, low
gestational age at birth was no longer associated with
respiratory mortality (ages 1-5 years: AHR for each addi-
tional week of gestation, 1.06 [95% CI, 0.82-1.36],
P=.65). However, in young adulthood, gestational age at
birth remained inversely associated with respiratory mor-
tality (ages 18-36 years: AHR, 0.82 [95% CI, 0.71-0.95],
P=.009). This association in young adulthood was due to
various diagnoses, of which the most common were
asthma,1 pneumonitis, other interstitial pulmonary dis-
eases, and pulmonary edema.
We also assessed the sensitivity of our all-cause mortal-
ity results to infection-related deaths by repeating our main
analyses after censoring all 243 of these deaths. The risk es-
timates in all age ranges (as reported in Table 2 of our ar-
ticle) remained virtually identical.
These supplemental findings suggest that gestational
age at birth has a strong inverse association with
infection-related mortality in early childhood, which
weakens but may not completely resolve in later child-
hood through young adulthood. In young adulthood, low
gestational age at birth was associated with increased
respiratory mortality even after excluding infection-
related deaths. Additional epidemiological and mechanis-
tic studies of the effect of preterm birth on immune func-
tion and infection risk throughout the life course are
warranted.
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Time-Limited Trials
To the Editor: The Commentary on time-limited trials (TLTs)
of treatment by Drs Quill and Holloway underscores the need
for an explicit process to better manage “major interven-
tions in circumstances in which the outcome is uncer-
tain.”1 The basic tenets of the authors’ proposal included
measurement of end points; agreement on a time point for
reevaluation of an individual’s therapeutic response; and re-
consideration of the intervention, with possible continua-
tion, dose reduction, or cessation based on response.
This process outlined for TLTs should pertain to all clini-
cal interventions, not simply to “major interventions” or to
those provided to people near the end of life. Having a pro-
cess in place to ensure net clinical benefit (ie, a balance be-
tween clinical response and toxicity) is important if iatro-
genic harm is to be minimized, patient burden reduced, and
health care costs contained. Clinicians must consistently ask
“Should this intervention be continued?” This evaluative pro-
cess will require an explicit set of measures matched to de-
fined outcomes. Clinicians should define and discuss the
therapeutic goals of a new intervention before reaching for
the prescription pad.
There is a research agenda corollary to this clinical mo-
tivation. A clear understanding of therapeutic intent re-
quires knowledge of the targeted level of prevention and the
time frame within which an individual’s benefit should ac-
crue.2 Consider statins for secondary prevention of cardio-
vascular disease. Should a person with metastatic lung can-
cer continue taking statins? Using principles of comparative
effectiveness research, carefully designed TLTs could gen-
erate evidence to inform such decisions; these trials’ re-
sults could apply to both population and patient levels, in-
forming both when to initiate therapies and when to stop
them. These studies are in their infancy.3,4
Physicians and patients require practical information to
guide decision making. Time-limited trials mirror more for-
mal n-of-1 trials that evaluate therapies objectively but are
often clinically infeasible. The ultimate in personalized medi-
cine, n-of-1 studies entail blinded evaluation of repeated
cycles alternating between therapies. Certain therapies are
ill-suited to this evaluation, particularly those with long de-
lays in onset of action or very long half-lives; n-of-1 trials
are inappropriate for patients with unstable disease.5 Lack-
ing the logistical challenges of n-of-1 studies, TLTs offer an
explicit process more suitable for guiding routine practice.
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In Reply: Although our Commentary focused exclusively
on TLTs toward the very end of life, we agree with Drs Ab-
ernethy and Currow that the concept has much broader ap-
plicability. In fact, virtually all interventions with uncer-
tain clinical effects on outcomes could be framed in these
terms, in which the probability of success, markers of re-
sponse, and associated time frames would be presented and
agreed upon upfront (eg, nearly all palliative chemo-
therapy regimens, biological treatments for autoimmune dis-
orders, and all major invasive interventions such as me-
chanical ventilation, renal dialysis, or feeding tubes).
In addition, as suggested by Abernethy and Currow, treat-
ments with effects that are realized only if one is likely to live
a long time (tight control of blood glucose, blood pressure,
or cholesterol) have much less relevance (and may even be
harmful) as prognosis worsens. In that sense, all medical treat-
ments deserve reevaluation at regular time intervals depend-
ing on changes in the patient’s condition and prognosis.
Time-limited trials may help us be more realistic, sys-
tematic, and regular in reassessments about what medicine
can and cannot do, thereby contributing simultaneously to
quality improvement and cost control.
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RESEARCH LETTER
POLST Registry Do-Not-Resuscitate Orders
and Other Patient Treatment Preferences
To the Editor: The Physician Orders for Life Sustaining Treat-
ment (POLST) form augments traditional methods for ad-
vance care planning by translating treatment preferences into
medical orders, including for cardiopulmonary resuscita-
tion (CPR), scope of treatment, artificial nutrition by tube,
and in some states, antibiotic use. Health professionals com-
plete forms based on conversations with willing patients,
primarily with advanced illness or frailty, or surrogates. These
orders then guide treatment in any setting. In 3 states, POLST
forms were effective in influencing the care that patients re-
ceived.1 POLST programs currently exist or are in develop-
ment in 34 states.2 We compared the preferences for other
treatments among persons with do-not-resuscitate (DNR)
orders and those with attempt CPR orders, using the first
year of Oregon POLST Registry data (December 3, 2009, to
December 2, 2010).
Methods. POLST includes 2 possible orders for resusci-
tation: do not attempt CPR (DNR) or attempt CPR. Scope-
of-treatment orders consist of limited additional interven-
tions and full treatment, which include hospitalization, and
comfort measures only. POLST forms identify patients using
name, birth date, sex, and address.
In Oregon, POLST forms are entered into a registry, al-
lowing emergency personnel and hospitals 24-hour access
to POLST information when the physical form cannot be
located during an emergency. Clinicians in Oregon are re-
quired by law to submit forms to the registry unless the pa-
tient opts out.
Data were analyzed using IBM SPSS Statistics version 19.0.0
and an online 95% confidence interval calculator.3 The in-
stitutional review boards of the Oregon Health & Science
University and Oregon State Public Health approved this
study and the waiver of informed consent.
Results. At the end of the first year, 25 142 people had
active POLST forms in the registry: 85.9% (21 599/25 142)
were aged 65 years or older, 61.0% (14 255/23 376) were fe-
male, and 40.4% (8014/19 859) resided in a rural area (de-
nominators 25 142 reflect missing data). There were 27.9%
(7026/25 142) with an order to attempt CPR and 72.1%
(18 116/25 142) with a DNR order. For patients with an at-
tempt CPR order, 75.7% (5218/6895) had orders for full treat-
ment, 21.6% (1492/6895) limited additional interven-
tions, and 2.7% (185/6895) comfort measures only (TABLE).
Of the 18 002 patients with a DNR order, 8929 (49.6%) had
orders for comfort measures only and 9073 (50.4%) had or-
ders for either full treatment or limited additional interven-
tions. Thus, half of patients with DNR orders would want
to be transported to the hospital if indicated, and half would
not unless comfort needs could not be met in their current
location.
Among those with POLST DNR orders, the probabilities
for having orders for other life-sustaining treatment ranged
from 0.101 to 0.557 except for full treatment and long-
term tube feeding (Table). Among those with POLST or-
ders to attempt CPR, the probabilities for having orders for
other life-sustaining treatments were higher for 6 of the 9
other orders, ranging from 0.021 to 0.739.
Comment. The Oregon POLST Registry allows exami-
nation of patient preferences beyond resuscitation status.
The number of registry submissions in its first year is note-
LETTERS
34 JAMA, January 4, 2012—Vol 307, No. 1 ©2012 American Medical Association. All rights reserved.
